BSE (formerly Bombay Stock Exchange) Selects ITRS to Strengthen Real-Time Monitoring and Operational Resilience February 23, 2026 Asia’s Oldest Stock Exchange Partners with ITRS to Strengthen Monitoring and Compliance
Schroders chief executive vows to keep Cazenove Capital February 23, 2026 Schroders’ chief executive has vowed that the company will retain its wealth management business following its £9.9bn takeover by US fund manager Nuveen. Richard Oldfield’s pledge comes after days of speculation surrounding the future of the wealth manager, driven by minimal detail on how it would be integrated into the business in its announcement just [...]
Ares Management Prices European Direct Lending CLO II at Over €300 Million February 23, 2026 Ares Management Corporation (NYSE: ARES) (“Ares”), a leading global alternative investment manager, announced today the pricing of its second European Direct Lending Collateralized Loan Obligation, Ares European Direct Lending CLO II (“EDL CLO II”), at over €300 million. Consistent with the underlying composition of its predecessor, EDL CLO II is a diversified CLO comprised entirely [...]
Compass Pathways Announces Pricing of $150 Million Public Offering February 23, 2026 Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, announced today the pricing of its public offering of 17,500,000 American Depositary Shares (“ADSs”) at a public offering price of $8.00 per ADS, each representing one ordinary share, and in lieu of ADSs, to certain institutional investors, pre-funded warrants [...]
TNS Launches TNSPay SmartRoute to Put Merchants and Acquirers in Control of Payment Routing February 23, 2026 New intelligent routing gives payments teams the power to set the rules, automate failover and keep revenue flowing – backed by global scale and enterprise-grade security.
Everbridge xMatters to Host London Event on the Future of Incident Management February 23, 2026 Everbridge, Inc., the global leader in High Velocity Critical Event Management (CEM) and national public warning solutions, will host an exclusive customer event on March 17 at the Churchill War Rooms in London, bringing together IT, DevOps, and operational leaders to discuss the evolving demands of modern incident management and operational resilience. This press release [...]
This ski holiday high in the Swiss Alps has serious Wes Anderson credentials February 23, 2026 #The Jungfrau region of Switzerland’s Bernese Oberland is home to some of the Alps’ finest skiing and most historic runs. Other destinations offer fashion parades of vintage furs, nightclub ceilings dripping with Dom Perignon, and truffled pizzas at £100 a pie. That’s not what you’ll find here. This is the anti-Zermatt, where après ski is [...]
Prothena Reports Fourth Quarter and Full Year 2025 Financial Results, and Provides Financial Guidance and Business Highlights February 23, 2026 Net cash used in operating and investing activities was $23.3 million and $163.7 million for the fourth quarter and full year of 2025, respectively; quarter-end cash and restricted cash position was $308.4 million Prothena expects the full year 2026 net cash used in operating and investing activities to be $50 to $55 million and expects to end the year with approximately $255 million in cash (midpoint). Financial guidance does not include the potential to earn up to $105 million in aggregate clinical milestone payments from strategic partners in 2026 Roche initiated the Phase 3 PARAISO trial evaluating prasinezumab in early-stage Parkinson’s disease in 4Q 2025; primary completion expected in 2029 Novo Nordisk initiated the Phase 3 CLEOPATTRA trial evaluating coramitug in ATTR amyloidosis with cardiomyopathy in 4Q 2025; primary completion expected in 2029 Bristol Myers Squibb fully enrolled the Phase 2 TargetTau-1 trial evaluating BMS-986446 in early Alzheimer’s disease with primary completion expected in 1H 2027, completed a Phase 1 trial evaluating a subcutaneous formulation of BMS-986446 and obtained Fast Track designation from the U.S. FDA for BMS-986446 for the treatment of Alzheimer’s disease Prothena presented preclinical data on its TDP-43 CYTOPE® program at Neuroscience 2025 (SfN) and at the International Symposium on ALS/MND demonstrating the potential of Prothena’s CYTOPE® technology to target intracellular disease pathways At the Extraordinary General Meeting on November 19, 2025 Prothena obtained shareholder approval to reduce share capital to create distributable reserves to support a share redemption program to be conducted in 2026 if deemed appropriate Potential to earn up to $105 million in aggregate clinical milestone payments by end of 2026 related to the advancement of both coramitug for ATTR amyloidosis with cardiomyopathy by Novo Nordisk and PRX019 for neurodegenerative diseases by Bristol Myers Squibb
‘Trust me’: Jamie Dimon to defend JP Morgan’s $2bn-a-week bill February 23, 2026 Jamie Dimon is set to defend JP Morgan’s $2bn-a-week cost bill today as analysts and shareholders gather for the banking giant’s annual investor day. The bank chief – generally considered to be the world’s most influential banker – unveiled higher-than-expected plans for 2026 spend at the beginning of the year. JP Morgan told markets spending [...]
CBRE IM Backs IPUT Real Estate Dublin with Significant Equity Commitment February 23, 2026 - CBRE IM to increase investment in IPUT by €175m - Capital will kick-start a €500m IPUT Real Estate’s office investment programme - IPUT Real Estate is a market leader with a €2.7bn portfolio